Rotavirus vaccine bovine reassortant - sanofi pasteur

Drug Profile

Rotavirus vaccine bovine reassortant - sanofi pasteur

Alternative Names: BRV vaccine - Shantha Biotechnics; BRV-TV; Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine - Shantha Biotechnics

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shantha Biotechnics
  • Class Rotavirus vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Rotavirus infections

Most Recent Events

  • 02 Mar 2017 No recent reports on development identified - Phase-III for Rotavirus infections (In infants, Prevention) in India (PO)
  • 14 Oct 2014 Phase-III clinical trials in Rotavirus infections (In infants, Prevention) in India (PO) (CTRI/2014/08/004893)
  • 30 Jun 2013 Shantha Biotechnics completes a phase I/II trial in Rotavirus infections (prevention, in infants) in India (CTRI2012-07-002820)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top